際際滷

際際滷Share a Scribd company logo

Jps Holding Sc

Download as PPTX, PDF
Jean-Philippe Sell竪s
Jean-Philippe Sell竪s

This document summarizes the business activities of JPSHolding, a life sciences company established in 1993. It provides licensing and product development services for pharmaceutical and medical products. Key areas of focus include portfolio management, product evaluation, regulatory submissions, and drug delivery technologies. JPSHolding licenses in pediatric drugs and food/medical products, and licenses out products like a skin ulcer treatment device and chemotherapy nausea treatment. It also develops its own products, such as a treatment for oral mucositis and a bipolar disorder drug formulation.

1 of 15
Download to read offline
JPSHolding SC Serving Life Sciences Industries Since 1993 Proprietary & Confidential;
Core Business Portfolio Management Products evaluation Products development Licensing-In and Out Expert Reports Regulatory dossiers development and submission: medicines, food supplements, dietary foods for special medical purposes. Drug Delivery Technology Proprietary & Confidential;
Licensing-in (for Clients) Paediatics drugs, medical food, food supplements BCAA Proprietary & Confidential;
Licensing-out AS 21: skin ulcers treatment (medical device) AS 22: mucitis treatment (medical device) Dualsetron速: Chemotherapy-Induced Nausea and Vomiting treatment (Internal) Biridone速: Bipolar disorders (Internal) Thixans速 technology: thixotropic formulation Proprietary & Confidential;
MEDICAL For of skin injuries AS-21 Proprietary & Confidential; CE Authorization 0459
FIRST SPECIFIC TREATMENT AGAINST: Bedsore (Superficial & Deep) Superficial & Deep Skin Injuries Pressure sore/Pressure ulcers Decubitus ulcers Diabetic skin ulcers A NEW TRIPLE ACTION APPROACH Proprietary & Confidential;
SALES New product: CE marking in August 2010 2 Trial launch in Finland January 2010 Sales Finland (Aktisor): 32 000 Launched in Austria 2010 10 000 units Israel- February 2011 Planned: Egypt, Middle East countries, India, Irak, S. Africa, Australia, Proprietary & Confidential;
AS 22 Specific treatment for Chemotherapy Induced oral mucositis (CIOM) Proprietary & Confidential;
AS 22 OROCHEM速 Mucitis following hemo and radiotherapy Colorless, odorless, sweet, viscous, 100 natural solution. Easy to apply, no side effects. Registered as a Class IIa medical device due to its mechanical effects. Proprietary & Confidential;
Dualsetron速 Fixed-Dosecombination for Chemotherapy-Induced Nausea And Vomiting treatment. Proprietary & Confidential;
Proprietary & Confidential;
Biridone速 Bipolar-disorders treament Patented formulation for once-day- treatment Proprietary & Confidential;
Development Status: CR formulation completed Analytical development completed Stability studies Pilot Pk study completed MBDD protocol completed Proprietary & Confidential;
THIXANS速: THE THIXOTROPIC DEVICE Pure or formulated active ingredient or microparticulate dosage forms (pellets, beadlets, spheroids etc..) manufactured by usual pharmaceutical technologies are embedded into a Thixotropic Cushion 速 either extemporaneously or regenerated by the microparticule itself. Proprietary and Confidential: deNovelda Farmaceutica
Thixotropic Diffusion coating Coating Drug Encapsulation Technologies Microspheres Thixotropic Cushion速 Proprietary and Confidential: deNovelda Farmaceutica

More Related Content

Jps Holding Sc

  • 1. JPSHolding SC Serving Life Sciences Industries Since 1993 Proprietary & Confidential;
  • 2. Core Business Portfolio Management Products evaluation Products development Licensing-In and Out Expert Reports Regulatory dossiers development and submission: medicines, food supplements, dietary foods for special medical purposes. Drug Delivery Technology Proprietary & Confidential;
  • 3. Licensing-in (for Clients) Paediatics drugs, medical food, food supplements BCAA Proprietary & Confidential;
  • 4. Licensing-out AS 21: skin ulcers treatment (medical device) AS 22: mucitis treatment (medical device) Dualsetron速: Chemotherapy-Induced Nausea and Vomiting treatment (Internal) Biridone速: Bipolar disorders (Internal) Thixans速 technology: thixotropic formulation Proprietary & Confidential;
  • 5. MEDICAL For of skin injuries AS-21 Proprietary & Confidential; CE Authorization 0459
  • 6. FIRST SPECIFIC TREATMENT AGAINST: Bedsore (Superficial & Deep) Superficial & Deep Skin Injuries Pressure sore/Pressure ulcers Decubitus ulcers Diabetic skin ulcers A NEW TRIPLE ACTION APPROACH Proprietary & Confidential;
  • 7. SALES New product: CE marking in August 2010 2 Trial launch in Finland January 2010 Sales Finland (Aktisor): 32 000 Launched in Austria 2010 10 000 units Israel- February 2011 Planned: Egypt, Middle East countries, India, Irak, S. Africa, Australia, Proprietary & Confidential;
  • 8. AS 22 Specific treatment for Chemotherapy Induced oral mucositis (CIOM) Proprietary & Confidential;
  • 9. AS 22 OROCHEM速 Mucitis following hemo and radiotherapy Colorless, odorless, sweet, viscous, 100 natural solution. Easy to apply, no side effects. Registered as a Class IIa medical device due to its mechanical effects. Proprietary & Confidential;
  • 10. Dualsetron速 Fixed-Dosecombination for Chemotherapy-Induced Nausea And Vomiting treatment. Proprietary & Confidential;
  • 12. Biridone速 Bipolar-disorders treament Patented formulation for once-day- treatment Proprietary & Confidential;
  • 13. Development Status: CR formulation completed Analytical development completed Stability studies Pilot Pk study completed MBDD protocol completed Proprietary & Confidential;
  • 14. THIXANS速: THE THIXOTROPIC DEVICE Pure or formulated active ingredient or microparticulate dosage forms (pellets, beadlets, spheroids etc..) manufactured by usual pharmaceutical technologies are embedded into a Thixotropic Cushion 速 either extemporaneously or regenerated by the microparticule itself. Proprietary and Confidential: deNovelda Farmaceutica
  • 15. Thixotropic Diffusion coating Coating Drug Encapsulation Technologies Microspheres Thixotropic Cushion速 Proprietary and Confidential: deNovelda Farmaceutica